Business
Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity
SAN FRANCISCO, January 08, 2026--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity
About this update from Pfizer, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3675,"height":1523,"url":"https://media.zenfs.com/en/business-wire.com/d501d44aa1c00fc87934067278bc6596"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mB8O1Z..VShTFmGNWL1ZvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM5ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d501d44aa1c00fc87934067278bc6596","width":960,"height":398},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Bmw9hRlZKM4Jm4DBL1C9wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05OTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d501d44aa1c00fc87934067278bc6596","width":1200,"height":497}},"lazy":false},{"type":"text","content":"Pfizer collaboration applies Gordian’s large-scale in vivo mosaic screening platform to prioritize novel obesity targets directly within visceral adipose tissue","length":160,"tagName":"p","attribs":{}},{"type":"text","content":"SAN FRANCISCO, January 08, 2026--(BUSINESS WIRE)--Gordian Bio, a biotechnology company pioneering large-scale in vivo functional genomics to unlock validated drug targets for chronic diseases, today announced a non-exclusive research collaboration with Pfizer to apply Gordian’s proprietary in vivo mosaic screening platform to accelerate the discovery of therapeutic targets for obesity.","length":388,"tagName":"p"},{"type":"text","content":"Under the terms of the collaboration, Gordian will perform a screen of hundreds of gene targets directly within visceral adipose tissue. Unlike traditional ex vivo or single-target models, Gordian’s platform can obtain in vivo transcriptional readouts for hundreds of targets.","length":276,"tagName":"p"},{"type":"text","content":""Obesity and metabolic syndrome are systemic and multi-tissue, and traditional target discovery tools simply can’t capture the interplay between fat depots and other organs," said Francisco LePort, Ph.D., CEO & Co-Founder, Gordian Bio. "Our in vivo mosaic screens allow us to ask hundreds of biological questions simultaneously inside living tissue, potentially providing a direct window into which gene targets truly shift adipocyte state, inflammation, insulin signaling, and metabolic pathways. We’re proud to see our platform advancing therapeutic discovery for one of the world’s most urgent heal...